Full Text Journal Articles by
Author Alberico L Catapano

Advertisement

Find full text journal articles






Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients.

Chiara Pavanello, Andrea Baragetti, Adriana Branchi, Liliana Grigore, Samuela Castelnuovo, Eleonora Giorgio, Alberico L Catapano, Laura Calabresi, Monica Gomaraschi,

Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are released in the cytosol where they can regulate their own synthesis and metabolism. When LAL is not active, as in case of genetic ... Read more >>

Pharmacol. Res. (Pharmacological research)
[2019, 147:104362]

Cited: 0 times

View full text PDF listing >>



Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.

Christie M Ballantyne, Ulrich Laufs, Kausik K Ray, Lawrence A Leiter, Harold E Bays, Anne C Goldberg, Erik Sg Stroes, Diane MacDougall, Xin Zhao, Alberico L Catapano,

AIMS:The aim of this study was to evaluate the low-density lipoprotein cholesterol lowering efficacy and safety of a bempedoic acid 180 mg and ezetimibe 10 mg fixed-dose combination in patients with hypercholesterolemia and a high risk of cardiovascular disease receiving maximally tolerated statin therapy. METHODS:This phase 3, double-blind clinical trial enrolled adult ... Read more >>

Eur J Prev Cardiol (European journal of preventive cardiology)
[2019, :2047487319864671]

Cited: 0 times

View full text PDF listing >>



Advertisement

Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.

Leopoldo Pérez de Isla, Kausik K Ray, Gerald F Watts, Raul D Santos, Rodrigo Alonso, Ovidio Muñiz-Grijalvo, Jose Luis Diaz-Diaz, Lina Badimon, Alberico L Catapano, Pedro Mata,

BACKGROUND AND AIMS:Patients with familial hypercholesterolaemia (FH) may require proprotein convertase subtilisin/kexin-type 9 (PCSK9) mAb as add-on therapy to achieve LDL-cholesterol (LDL-C) goals. However, the current cost of these therapies means that choosing suitable patients is based on consensus or clinical judgement rather than a quantitative risk assessment. We used ... Read more >>

Atherosclerosis (Atherosclerosis)
[2019, 286:40-45]

Cited: 0 times

View full text PDF listing >>



Cholesterol metabolism, pancreatic β-cell function and diabetes.

Carla Perego, Lorenzo Da Dalt, Angela Pirillo, Alessandra Galli, Alberico L Catapano, Giuseppe D Norata,

Cholesterol plays an essential role in determining cell membrane physico-chemical characteristics and functions. A proper membrane structure is critical in pancreatic β-cells for glucose-mediated insulin secretion, and alterations in cellular cholesterol content may negatively affect this process, leading to β-cell dysfunction. The low density lipoprotein receptor (LDL-R) appears to play ... Read more >>

Biochim Biophys Acta Mol Basis Dis (Biochimica et biophysica acta. Molecular basis of disease)
[2019, 1865(9):2149-2156]

Cited: 0 times

View full text PDF listing >>



Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes.

Gareth S D Purvis, Massimo Collino, Rodrigo A Loiola, Andrea Baragetti, Fausto Chiazza, Martina Brovelli, Madeeha H Sheikh, Debora Collotta, Alessia Cento, Raffaella Mastrocola, Manuela Aragno, Juan C Cutrin, Chris Reutelingsperger, Liliana Grigore, Alberico L Catapano, Magdi M Yaqoob, Giuseppe Danilo Norata, Egle Solito, Christoph Thiemermann,

Annexin A1 (ANXA1) is an endogenously produced anti-inflammatory protein, which plays an important role in the pathophysiology of diseases associated with chronic inflammation. We demonstrate that patients with type-2 diabetes have increased plasma levels of ANXA1 when compared to normoglycemic subjects. Plasma ANXA1 positively correlated with fatty liver index and ... Read more >>

Front Immunol (Frontiers in Immunology)
[2019, 10:571]

Cited: 1 time

View full text PDF listing >>



Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials.

Manuela Casula, Elena Olmastroni, Mezio T Boccalari, Elena Tragni, Angela Pirillo, Alberico L Catapano,

The therapy with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors efficiently reduces plasma cholesterol levels, which has been recently associated with improvement in cardiovascular outcomes. This meta-analysis aimed at investigating the safety and efficacy of treatment with the clinically available anti-PCSK9 monoclonal antibodies (mAbs) in all published randomized clinical trials ... Read more >>

Pharmacol. Res. (Pharmacological research)
[2019, 143:143-150]

Cited: 0 times

View full text PDF listing >>



Mendelian Randomization Study of ACLY and Cardiovascular Disease.

Brian A Ference, Kausik K Ray, Alberico L Catapano, Thatcher B Ference, Stephen Burgess, David R Neff, Clare Oliver-Williams, Angela M Wood, Adam S Butterworth, Emanuele Di Angelantonio, John Danesh, John J P Kastelein, Stephen J Nicholls,

BACKGROUND:ATP citrate lyase is an enzyme in the cholesterol-biosynthesis pathway upstream of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the target of statins. Whether the genetic inhibition of ATP citrate lyase is associated with deleterious outcomes and whether it has the same effect, per unit decrease in the low-density lipoprotein (LDL) cholesterol level, ... Read more >>

N. Engl. J. Med. (The New England journal of medicine)
[2019, 380(11):1033-1042]

Cited: 2 times

View full text PDF listing >>



Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.

Kausik K Ray, Harold E Bays, Alberico L Catapano, Narendra D Lalwani, LeAnne T Bloedon, Lulu R Sterling, Paula L Robinson, Christie M Ballantyne, ,

BACKGROUND:Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recommended statin therapy. METHODS:We conducted a randomized, controlled ... Read more >>

N. Engl. J. Med. (The New England journal of medicine)
[2019, 380(11):1022-1032]

Cited: 0 times

View full text PDF listing >>



Reprint of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series.

Brian A Ference, Ian Graham, Lale Tokgozoglu, Alberico L Catapano,

People who maintain ideal cardiovascular heath have a low lifetime risk of cardiovascular disease. Therefore, encouraging people to achieve ideal cardiovascular health represents an important opportunity to improve the prevention of cardiovascular disease. However, preventing cardiovascular disease by promoting ideal cardiovascular health requires shifting the focus from treating disease after ... Read more >>

J. Am. Coll. Cardiol. (Journal of the American College of Cardiology)
[2018, 72(23 Pt B):2980-2995]

Cited: 0 times

View full text PDF listing >>



Lipid Lowering and Incidence of Cataract, a Role for Fibrates.

Manuela Casula, Angela Pirillo, Alberico L Catapano,

Clin. Pharmacol. Ther. (Clinical pharmacology and therapeutics)
[2019, 105(2):318-319]

Cited: 0 times

View full text PDF listing >>



Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.

Laurens F Reeskamp, John J P Kastelein, Patrick M Moriarty, P Barton Duell, Alberico L Catapano, Raul D Santos, Christie M Ballantyne,

BACKGROUND AND AIMS:Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and increased cardiovascular disease risk. Despite multiple LDL-C-lowering therapies, many HeFH patients do not reach LDL-C targets. Mipomersen, an antisense oligonucleotide against apolipoprotein B (apoB), might further lower LDL-C in HeFH patients. ... Read more >>

Atherosclerosis (Atherosclerosis)
[2019, 280:109-117]

Cited: 0 times

View full text PDF listing >>



Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study.

Peter E Penson, D Leann Long, George Howard, Peter P Toth, Paul Muntner, Virginia J Howard, Monica M Safford, Steven R Jones, Seth S Martin, Mohsen Mazidi, Alberico L Catapano, Maciej Banach,

Aims:Recent findings have demonstrated the important contribution of inflammation to the risk of cardiovascular disease (CVD) in individuals with optimally managed low density lipoprotein cholesterol (LDL-C). We explored relationships between LDL-C, high sensitivity C-reactive protein (hs-CRP), and clinical outcomes in a free-living US population. Methods and results:We used data from ... Read more >>

Eur. Heart J. (European heart journal)
[2018, 39(40):3641-3653]

Cited: 1 time

View full text PDF listing >>



Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series.

Brian A Ference, Ian Graham, Lale Tokgozoglu, Alberico L Catapano,

People who maintain ideal cardiovascular heath have a low lifetime risk of cardiovascular disease. Therefore, encouraging people to achieve ideal cardiovascular health represents an important opportunity to improve the prevention of cardiovascular disease. However, preventing cardiovascular disease by promoting ideal cardiovascular health requires shifting the focus from treating disease after ... Read more >>

J. Am. Coll. Cardiol. (Journal of the American College of Cardiology)
[2018, 72(10):1141-1156]

Cited: 1 time

View full text PDF listing >>



Familial hypercholesterolemia treatments: Guidelines and new therapies.

Frederick J Raal, G Kees Hovingh, Alberico L Catapano,

Familial hypercholesterolemia (FH) is a genetic disorder resulting from mutations in genes encoding proteins involved in the metabolism of low density lipoproteins (LDL) and characterized by premature cardiovascular disease due to the exposure to high levels of LDL-cholesterol (LDL-C) from birth. Thus, the early identification of FH subjects, followed by ... Read more >>

Atherosclerosis (Atherosclerosis)
[2018, 277:483-492]

Cited: 0 times

View full text PDF listing >>



Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

, Antonio J Vallejo-Vaz, Martina De Marco, Christophe A T Stevens, Asif Akram, Tomas Freiberger, G Kees Hovingh, John J P Kastelein, Pedro Mata, Frederick J Raal, Raul D Santos, Handrean Soran, Gerald F Watts, Marianne Abifadel, Carlos A Aguilar-Salinas, Mutaz Al-Khnifsawi, Fahad A AlKindi, Fahad Alnouri, Rodrigo Alonso, Khalid Al-Rasadi, Ahmad Al-Sarraf, Tester F Ashavaid, Christoph J Binder, Martin P Bogsrud, Mafalda Bourbon, Eric Bruckert, Krzysztof Chlebus, Pablo Corral, Olivier Descamps, Ronen Durst, Marat Ezhov, Zlatko Fras, Jacques Genest, Urh Groselj, Mariko Harada-Shiba, Meral Kayikcioglu, Katarina Lalic, Carolyn S P Lam, Gustavs Latkovskis, Ulrich Laufs, Evangelos Liberopoulos, Jie Lin, Vincent Maher, Nelson Majano, A David Marais, Winfried März, Erkin Mirrakhimov, André R Miserez, Olena Mitchenko, Hapizah M Nawawi, Børge G Nordestgaard, György Paragh, Zaneta Petrulioniene, Belma Pojskic, Arman Postadzhiyan, Ashraf Reda, Željko Reiner, Wilson E Sadoh, Amirhossein Sahebkar, Abdullah Shehab, Aleksander B Shek, Mario Stoll, Ta-Chen Su, Tavintharan Subramaniam, Andrey V Susekov, Phivos Symeonides, Myra Tilney, Brian Tomlinson, Thanh-Huong Truong, Alexandros D Tselepis, Anne Tybjærg-Hansen, Alejandra Vázquez-Cárdenas, Margus Viigimaa, Branislav Vohnout, Elisabeth Widén, Shizuya Yamashita, Maciej Banach, Dan Gaita, Lixin Jiang, Lennart Nilsson, Lourdes E Santos, Heribert Schunkert, Lale Tokgözoğlu, Josip Car, Alberico L Catapano, Kausik K Ray, ,

BACKGROUND AND AIMS:Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. METHODS:Lead Investigators from countries ... Read more >>

Atherosclerosis (Atherosclerosis)
[2018, 277:234-255]

Cited: 4 times

View full text PDF listing >>



Epidemiology of cardiovascular risk factors in two population-based studies.

Elena Olmastroni, Evgeny V Shlyakhto, Aleksandra O Konradi, Oxana P Rotar, Asiiat S Alieva, Maria A Boyarinova, Andrea Baragetti, Liliana Grigore, Fabio Pellegatta, Elena Tragni, Alberico L Catapano, Manuela Casula,

We aimed to compare cardiovascular risk factors prevalence in Italy and Russia through cross-sectional database analysis. The study has been based on data from ESSE-RF and from baseline of PLIC study, two population-based epidemiological studies aimed to investigate prevalence of risk factors and evaluating contribution of traditional and new risk ... Read more >>

Atheroscler Suppl (Atherosclerosis. Supplements)
[2018, 35:e14-e20]

Cited: 0 times

View full text PDF listing >>



Use of proton pump inhibitors and risk of ischemic events in the general population.

Manuela Casula, Lorenza Scotti, Federica Galimberti, Francesco Mozzanica, Elena Tragni, Giovanni Corrao, Alberico L Catapano,

BACKGROUND AND AIMS:A potential increased risk of cardiovascular events has been suggested for proton pump inhibitors (PPIs), the most commonly prescribed drugs for the management of upper gastrointestinal disorders. We aimed to estimate the risk of hospitalization for cardio/cerebrovascular (CV) events in a cohort of incident PPI users. METHODS:A nested ... Read more >>

Atherosclerosis (Atherosclerosis)
[2018, 277:123-129]

Cited: 0 times

View full text PDF listing >>



Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.

François Mach, Kausik K Ray, Olov Wiklund, Alberto Corsini, Alberico L Catapano, Eric Bruckert, Guy De Backer, Robert A Hegele, G Kees Hovingh, Terry A Jacobson, Ronald M Krauss, Ulrich Laufs, Lawrence A Leiter, Winfried März, Børge G Nordestgaard, Frederick J Raal, Michael Roden, Raul D Santos, Evan A Stein, Erik S Stroes, Paul D Thompson, Lale Tokgözoglu, Georgirene D Vladutiu, Baris Gencer, Jane K Stock, Henry N Ginsberg, M John Chapman, ,

To objectively appraise evidence for possible adverse effects of long-term statin therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for haemorrhagic stroke or cataract.A literature search covering 2000-2017 was performed. The Panel critically appraised the data and agreed by consensus on the categorization of reported adverse effects. ... Read more >>

Eur. Heart J. (European heart journal)
[2018, 39(27):2526-2539]

Cited: 8 times

View full text PDF listing >>



New prospects for PCSK9 inhibition?

Ulf Landmesser, M John Chapman, Jane K Stock, Pierre Amarenco, Jill J F Belch, Jan Borén, Michel Farnier, Brian A Ference, Stephan Gielen, Ian Graham, Diederick E Grobbee, G Kees Hovingh, Thomas F Lüscher, Massimo F Piepoli, Kausik K Ray, Erik S Stroes, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano, Fausto Pinto, Lale Tokgözoglu, Jeroen J Bax, Alberico L Catapano, ,

Eur. Heart J. (European heart journal)
[2018, 39(27):2600-2601]

Cited: 2 times

View full text PDF listing >>



Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.

Brian A Ference, Christopher P Cannon, Ulf Landmesser, Thomas F Lüscher, Alberico L Catapano, Kausik K Ray,

Eur. Heart J. (European heart journal)
[2018, 39(27):2540-2545]

Cited: 13 times

View full text PDF listing >>



High density lipoprotein cholesterol and cancer: Marker or causative?

Matteo Pirro, Biagio Ricciuti, Daniel J Rader, Alberico L Catapano, Amirhossein Sahebkar, Maciej Banach,

The relationship between high-density lipoproteins (HDLs), HDL-cholesterol (HDLC) and cancer incidence and mortality is controversial. Although most studies conducted so far, including well-designed prospective studies and meta-analyses, have revealed a significant inverse association between HDL-C levels and cancer risk, several confounding factors and opposite results showing either a direct or ... Read more >>

Prog. Lipid Res. (Progress in lipid research)
[2018, 71:54-69]

Cited: 1 time

View full text PDF listing >>



Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.

Marcello Arca, David Ansell, Maurizio Averna, Francesca Fanelli, Katherine Gorcyca, Şerban R Iorga, Aldo P Maggioni, Georges Paizis, Radovan Tomic, Alberico L Catapano,

BACKGROUND AND AIMS:Statin utilization and lipid goal achievement were estimated in a large sample of Italian patients at high/very-high cardiovascular (CV) risk. METHODS:Patients aged ≥18 years with a valid low-density lipoprotein cholesterol (LDL-C) measurement in 2015 were selected from the IMS Health Real World Data database; non-high-density lipoprotein cholesterol (non-HDL-C) ... Read more >>

Atherosclerosis (Atherosclerosis)
[2018, 271:120-127]

Cited: 0 times

View full text PDF listing >>



New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.

Ian Graham, Chuck Shear, Pieter De Graeff, Caroline Boulton, Alberico L Catapano, Wendy Gattis Stough, Stefan C Carlsson, Guy De Backer, Joseph Emmerich, Scott Greenfeder, Albert M Kim, Dominik Lautsch, Tu Nguyen, Steven E Nissen, Krishna Prasad, Kausik K Ray, Jennifer G Robinson, William J Sasiela, Karsten Bruins Slot, Erik Stroes, Tom Thuren, Bart Van der Schueren, Maja Velkovski-Rouyer, Scott M Wasserman, Olov Wiklund, Emmanouil Zouridakis, ,

The very high occurrence of cardiovascular events presents a major public health issue, because treatment remains suboptimal. Lowering LDL cholesterol (LDL-C) with statins or ezetimibe in combination with a statin reduces major adverse cardiovascular events. The cardiovascular risk reduction in relation to the absolute LDL-C reduction is linear for most ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2018, 4(2):119-127]

Cited: 1 time

View full text PDF listing >>



Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis.

Madhav Kishore, Kenneth C P Cheung, Hongmei Fu, Fabrizia Bonacina, Guosu Wang, David Coe, Eleanor J Ward, Alessandra Colamatteo, Maryam Jangani, Andrea Baragetti, Giuseppe Matarese, David M Smith, Robert Haas, Claudio Mauro, David C Wraith, Klaus Okkenhaug, Alberico L Catapano, Veronica De Rosa, Giuseppe D Norata, Federica M Marelli-Berg,

Immunity (Immunity)
[2018, 48(4):831-832]

Cited: 3 times

View full text PDF listing >>



2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

Ulf Landmesser, M John Chapman, Jane K Stock, Pierre Amarenco, Jill J F Belch, Jan Borén, Michel Farnier, Brian A Ference, Stephan Gielen, Ian Graham, Diederick E Grobbee, G Kees Hovingh, Thomas F Lüscher, Massimo F Piepoli, Kausik K Ray, Erik S Stroes, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano, Fausto Pinto, Lale Tokgözoglu, Jeroen J Bax, Alberico L Catapano,

Eur. Heart J. (European heart journal)
[2018, 39(14):1131-1143]

Cited: 25 times

View full text PDF listing >>



Advertisement

Disclaimer
1.5757 s